Prediction of hERG inhibition of drug discovery compounds using biomimetic HPLC measurements
The major causes of failure of drug discovery compounds in clinics are the lack of efficacy and toxicity. To reduce late-stage failures in the drug discovery process, it is essential to estimate early the probability of adverse effects and potential toxicity. Cardiotoxicity is one of the most often...
Main Authors: | Chrysanthos Stergiopoulos, Fotios Tsopelas, Klara Valko |
---|---|
Format: | Article |
Language: | English |
Published: |
International Association of Physical Chemists (IAPC)
2021-06-01
|
Series: | ADMET and DMPK |
Online Access: | https://www.pub.iapchem.org/ojs/index.php/admet/article/view/995 |
Similar Items
-
Inhibition of Anti-arrhythmic Drugs on hERG potassium channel
by: Yun-Lun Huang, et al.
Published: (2013) -
An Update on the Structure of hERG
by: Andrew Butler, et al.
Published: (2020-01-01) -
Mitragynine, an euphoric compound inhibits hERG1a/1b channel current and upregulates the complexation of hERG1a-Hsp90 in HEK293-hERG1a/1b cells
by: Adenan, M.I, et al.
Published: (2019) -
Stereoselective inhibition of the hERG1 potassium channel
by: Liliana eSintra Grilo, et al.
Published: (2010-11-01) -
Early identification of hERG liability in drug discovery programs by automated patch clamp
by: Timm eDanker, et al.
Published: (2014-09-01)